XML 20 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:    
Net loss $ (35,041) $ (19,193)
Adjustments to reconcile net loss to net cash used in operations:    
Depreciation and amortization 5,361 5,341
Stock-based compensation expense 4,729 4,661
Provision for excess and obsolete inventory 1,467 1,902
Deferred income taxes 24 (2,403)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability 70 (5,850)
China dissolution 1,921 0
Non-cash interest income 0 (49)
Other non-cash items 600 525
Unrealized foreign exchange gain on cash and cash equivalents (226) (186)
Changes in operating asset and liability accounts:    
Accounts receivable (10,360) (3,760)
Inventory (14,796) (3,307)
Prepaid expenses and other current assets (5,757) (420)
Accounts payable and accrued expenses 8,660 4,695
Deferred revenue 20,863 (933)
Net cash used in operating activities (22,485) (18,977)
Cash flows from investing activities:    
Purchase of property, plant and equipment (1,236) (938)
Cash paid for acquisition, net of cash received 0 (11,479)
Proceeds from the maturity of marketable securities 0 5,189
Change in other assets (281) 65
Net cash used in investing activities (1,517) (7,163)
Cash flows from financing activities:    
Repurchase of treasury stock 0 (46)
Repayment of debt (73) (53)
Proceeds from exercise of employee stock options and ESPP 235 241
Net cash provided by financing activities 162 142
Effect of exchange rate changes on cash, cash equivalents and restricted cash 29 (55)
Net decrease in cash, cash equivalents and restricted cash (23,811) (26,053)
Cash, cash equivalents and restricted cash at beginning of year 49,486 75,539
Cash, cash equivalents and restricted cash at end of year 25,675 49,486
Supplemental schedule of cash flow information:    
Cash paid for income taxes, net of refunds 350 531
Non-cash investing and financing activities    
Issuance of common stock in connection with the purchase of Neeltran, Inc. 0 4,387
Issuance of common stock to settle liabilities $ 623 $ 2,761